ArticleBMJ open gastroenterology2026
Antiviral treatment and statin use and risk of decompensated cirrhosis in patients with hepatitis C: a time-dependent analysis of a retrospective cohort study.
Article in BMJ open gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveSustained virological response (SVR) in patients with hepatitis C virus (HCV) is associated with slower progression of cirrhosis. Likewise, statin treatment is associated with delayed cirrhosis progression, but most studies of statin use in chronic liver disease include patients with multiple disease aetiologies. We use a unique time-dependent analysis to evaluate the interplay between antiviral treatment and statin use and the risk of decompensated cirrhosis (DC) among patients with HCV over time.
methodsUsing data from the US-based retrospective Chronic Hepatitis Cohort Study, we evaluated the impact of time-varying antiviral treatment status and statin use on risk of DC after propensity score weighting for HCV treatment selection bias. We used a pseudo-observation approach to compress data into discrete time intervals using 1 year as the landmark interval (INT), where each 'INT' has a value of 0 (at index) through 15 (15 years postindex) or the date of last follow-up. Time from the index date to the event of incident DC was the main outcome of interest. Death was considered a competing risk.
resultsA total of 16 275 patients with HCV (with 93 343 intervals) were observed (2006-2018), with 1718 incidents of DC and 2398 deaths. By year 15, the proportion of patients without antiviral treatment decreased from 36% to 11%; statin use increased from 12% to 28%. Compared with no antiviral treatment, SVR was associated with reduced risk of DC (SVR: adjusted HR (aHR) 0.17, 95% CI 0.14 to 0.21). Statin use was also associated with lower risk of decompensation (aHR 0.68, 95% CI 0.58 to 0.80) independent of cirrhosis status; such reduced risks varied but were sustained across treatment status groups. Additional risk factors included body mass index >25, male sex and multiple comorbidities.
conclusionsBoth SVR and statin treatment were associated with reduced risk of decompensation in patients with HCV. These findings may inform clinical management to reduce the risk of DC among patients with HCV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.